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Edited by Judit Ova´diAbstract Rad23 proteins bind ubiquitinated substrates and the
proteasome, consistent with an important role in protein degrada-
tion. Although human Rad23 proteins (hHR23A and hHR23B)
have redundant roles in DNA repair, we determined they formed
distinct interactions with proteasomes andmultiubiquitinated pro-
teins, but similar binding toAtaxin-3. Threonine-79 contributed to
the weak proteasome-binding property of hHR23A, and its con-
version to proline (T79P), which is the residue present in hHR23B,
increased proteasome interaction. We also determined that
hHR23A and hHR23B could be co-puriﬁed with unique proteo-
lytic and stress-responsive factors from human breast cancer tis-
sues, indicating that they have unique functions in vivo.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Ataxin-31. Introduction
Rad23 contains an amino-terminal ubiquitin-like (UbL)
domain [1] that can bind the proteasome [2], and two ubiqui-
tin-associated (UBA) domains [3,4] that bind Ub [5,6], and
multiubiquitinated substrates [7,8]. Rad23/proteasome binding
is required for eﬃcient nucleotide excision repair (NER) [1,9],
which is the primary mechanism for removing UV-induced
DNA lesions. Although hHR23A and hHR23B are redundant
in a reconstituted NER reaction [10], the requirement for two
Rad23 homologs in metazoans is unresolved. NER is not re-
quired for viability, although the loss of both proteins causes
embryonic lethality in mice [11]. This ﬁnding indicates that
Rad23 has additional functions that are required for cell sur-
vival [8,12].
To identify functional diﬀerences between hHR23A and
hHR23B we examined their interactions with the proteasome,
multiubiquitinated (multi-Ub) proteins, and other cellular
factors. We found that both proteins formed equivalent inter-
action with Ataxin-3 [13], a causative agent in the neurodegen-
erative disease spinocerebellar ataxia-3 (SCA3). However,
hHR23A and hHR23B formed distinct interactions with the
proteasome and multi-Ub proteins. A single amino acid resi-
due in hHR23A (threonine-79) was associated with its reduced
interaction with the proteasome. Conversion of threonine-79*Corresponding author. Fax: +1 732 235 5417.
E-mail address: maduraki@umdnj.edu (K. Madura).
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doi:10.1016/j.febslet.2006.05.012to proline, which is the residue present in hHR23B, signiﬁ-
cantly increased hHR23A/proteasome binding, without aﬀect-
ing its association with ubiquitinated proteins, or Ataxin-3. We
identiﬁed unique binding partners for hHR23A and hHR23B
in primary breast cancer tissue, supporting our hypothesis that
human Rad23 proteins have certain non-overlapping cellular
functions, despite similar roles in NER.2. Materials and methods
2.1. Plasmids and strains
TheUbL domains from human hHR23A (1–79) and hHR23B (1–78),
and yeast Rad23 (1–77) andDsk2 (1–76) were cloned into pCBGST1 [2].
All the constructs were generated using polymerase chain reaction
(PCR), and cloned using appropriate DNA restriction sites. Expression
from pCBGST1 is regulated by the PCUP1 promoter. Therefore, expres-
sion was initiated by the addition of 100 lMCuSO4 to the growth med-
ium.Cellswere pelleted (after 4 h growth at 30 C), resuspended in buﬀer
containing 1% Triton-X 100 and a cocktail of protease inhibitors, and
lysed bymechanical agitation using 450 l glass beads and a bead-disrup-
tor. Constructs for expression in E. coli were generated by PCR, and
cloned into pGEX-2TK (Amersham-Bioscience). Mutations in the
UbL domains were generated by PCR using DNA oligonucleotides. In
all cases, multiple isolates were subjected toDNA sequencing to conﬁrm
the authenticity of the mutation (IDT Integrated Technologies).
2.2. Protein extracts and puriﬁcation
GST-UbL proteins were puriﬁed from yeast, as described [2]. GST-
UbL proteins were immobilized on glutathione-Sepharose, and inter-
acting factors were released in SDS-containing buﬀer, separated in
SDS–PAGE, and transferred to nitrocellulose. The ﬁlters were stained
with Ponceau S prior to immunoblotting. The puriﬁcation of GST-
fusion proteins from E. coli was described [14].
2.3. Cell lines and tissue extracts
Cultured human cell lines (ATCC) were grown at 37 C with 5%
CO2 and collected when growth approached 90% conﬂuence. Cell pel-
lets and primary human tissue specimens were suspended in Buﬀer A,
lysed by sonication, and extracts prepared as described [15]. One mil-
ligram of extract was applied to the GST-UbL matrices, incubated for
4 h at 4 C with gentle mixing. The beads were washed three times with
Buﬀer A, suspended in SDS-containing buﬀer and the bound proteins
resolved by SDS–PAGE.
2.4. Proteasome activity measurement
The chymotrypsin-like proteasome activity was measured with
40 lM substrate (N-Suc-LLVY-AMC, Boston Biochem) [15], using a
Turner-700 ﬂuorometer. All measurements were conducted in tripli-
cate, and multiple independent extracts were characterized.
2.5. Immunological methods
Antibodies against proteasome subunits (BioMol International, LP),
eEF1A (Upstate Biotechnology, NY), ubiquitin (Sigma Chemical
Co., St. Louis, MO), vimentin (Lab Vision Corp., Fremont, CA), E1blished by Elsevier B.V. All rights reserved.
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luted as recommended by the manufacturers. Antibodies against Atax-
in-3 (and yeast Rpt1), were generated at Pocono Rabbits (PA). The
normal Ataxin-3 protein, containing 20 polyglutamine repeats (Atax-
in-3Q20), was expressed in E. coli as a GST-fusion protein in the vector
pGEX-2TK. Expression of the GST-Ataxin3 fusion protein was in-
duced by the addition of IPTG to the growth medium. The protein
was puriﬁed on GST-Sepharose. Ataxin-3 was released from the beads
following treatment with thrombin, and thrombin was selectively re-
moved from the supernatant by incubation with benzamidine-Sephar-
ose (Pharmacia). Ataxin-3 (lacking GST), was concentrated by
ﬁltration, and used as an antigen for the preparation of antibodies.
Immunoblots were subjected to enhanced chemiﬂuorescence and the
X-ray ﬁlms quantiﬁed using Kodak 1D densitometry software
(Rochester, NY). Multiple exposures were examined.
2.6. Mass spectrometry
Protein bands were detected with Coomassie blue, excised, and iden-
tiﬁed by mass spectrometry at the Center for Advanced Proteomics
Research-New Jersey Medical School. The number of positive identiﬁ-
cations for several putative targets is indicated below in parenthesis.
Isopeptidase T (11 peptides); Ubiquitin activating enzyme E1 (6 pep-
tides); Translation elongation factor 2 (18 peptides); Translation elon-
gation factor 1a (9 peptides); Heat shock cognate 71 kDa (4 peptides);
BRCA1 (4 peptides); BRCA2 (2 peptides); Vimentin (60 peptides);
mKIAA0467 (3 peptides).3. Results
3.1. UbL domain from hHR23B, but not hHR23A, binds yeast
proteasome
UbL domains from yeast Rad23 (residues 1–78) and Dsk2
(1–78), as well as human hHR23A (1–79) and hHR23B (1–
78) were fused to glutathione S-transferase (GST), and
expressed in yeast. Protein extracts were incubated with
glutathione-Sepharose to isolate the fusion proteins, and the
co-puriﬁcation of proteasomes was examined. We conﬁrmed
a strong interaction between the proteasome and the UbL do-
main from yeast Rad23 (Fig. 1, lane 1). As expected, no inter-
action was observed with GST, or ubiquitin (lane 3), since
mono-Ub does not show appreciable aﬃnity for the protea-
some [16]. The UbL domain of yeast Dsk2 showed weak inter-
action, consistent with previous ﬁndings [17]. Despite
signiﬁcant sequence similarity (75%) between human UbL-
hHR23A and UbL-hHR23B (hereafter termed UbL-A and
UbL-B), only the latter bound the yeast proteasome (lane 6).
The diﬀerence in this interaction with yeast proteasomes sug-Fig. 1. Human UbL-A and UbL-B show diﬀerential interaction with
yeast proteasomes. The interaction between yeast proteasomes and
GST fusions encoding ubiquitin (Ub), and UbL domains from Rad23
(R23) Dsk2, hHR23A (UbL-A) and hHR23B (UbL-B) was deter-
mined, using antibodies against proteasome subunits Rpt1, Rpt6 and
Pre1-FLAG.gested that they might have unique functions in protein degra-
dation. Therefore, we sought to conﬁrm these observations in
human cell extracts.
3.2. UbL domains in hHR23A and hHR23B display unique
interactions with the proteasome in mammalian cell extracts
Protein extracts from MCF10A, Hut78, and CHO cells were
applied to GST-UbL-A and GST-UbL-B. Multiple cell lines
were examined to avoid any cell-type speciﬁc eﬀects. Ponceau
S staining showed equal amounts of GST-UbL-A and GST-
UbL-B were present on the aﬃnity beads (upper panel in
Fig. 2A). However, we detected 3-fold higher levels of a-pro-
teasome subunits with UbL-B (mean 2.94« 1.01; P < 0.001).
High levels of 19S subunits Rpt1 and Rpn2 were also detected
with UbL-B (data not shown; but see Fig. 3C) and, as ex-
pected, the chymotryptic activity associated with GST-UbL-
B was higher (Fig. 2B). Similar ﬁndings were observed in
ZR-75-1 breast cancer cells (data not shown), conﬁrming that
these binding diﬀerences between UbL-A and UbL-B are not
cell-type speciﬁc. Addition of epoxomicin completely inhibited
the chymotryptic activity, verifying the speciﬁcity of the pro-
teasome assay (data not shown). The results obtained from
14 independent proteasome activity measurements were ad-
justed to the activity puriﬁed with UbL-A. Collectively, these
results showed that the dissimilar proteasome-binding proper-
ties of UbL-A and -B are intrinsic properties of these domains,
and is likely to have functional signiﬁcance.
3.3. Full-length hHR23 proteins also display unique proteasome-
binding properties
A previous study suggested that UBA and UbL domains in
Rad23 might form an intramolecular interaction [17], which
could aﬀect Rad23/proteasome binding by restricting the avail-
ability of the UbL domain. To determine if full-length hHR23
proteins also displayed distinct proteasome-binding properties
we immobilized GST-tagged hHR23A and hHR23B (that were
puriﬁed from E. coli), and incubated with Hut78 protein ex-
tracts. Proteasome activity measurements from 10 independent
assays were averaged and plotted (mean 2.39« 0.98; P <
0.001). We detected signiﬁcantly higher levels of proteasome
subunits, and proteasome activity, in association with hHR23B
(Fig. 2C andD), consistent with the results obtainedwithUbL-B
using the same extracts (Fig. 2A).
3.4. Distinct pattern of ubiquitinated species bind hHR23A and
hHR23B
The UBA domain is a small, independently folded structure
of 40 amino acid residues that is present in a large number of
proteins. A UBA domain in human Rad23 was ﬁrst reported
to bind the Vpr protein that is encoded by HIV-1. However,
subsequent studies reported that UBA domains could interact
with multi-Ub chains, and multiubiquitinated proteins (via the
multi-Ub chain). Rad23 proteins contain two UBA domains,
and the amino-terminal UBA1 domain typically forms a stron-
ger interaction with multi-Ub chains [5,6]. However, both do-
mains are required for maximum binding to ubiquitinated
proteins [8]. Intriguingly, only the carboxy terminal UBA2 do-
main has been shown to bind other proteins, such as Vpr, p300
and MPG, suggesting that the two UBA sequences are func-
tionally distinct.
We examined the interaction between multi-Ub proteins and
full-length hHR23 proteins, as well as isolated UBA domains.
Fig. 2. Human Rad23 proteins show diﬀerential binding to proteasomes in mammalian extracts. (A) Equal amount GST-UbL-A and GST-UbL-B
were incubated with extracts prepared from MCF10A, Hut78 and CHO cells. (B) Proteasome activity associated with GST-UbL-A beads was
determined, and standardized to 1. Relative activity associated with GST-UbL-B is shown (*, P < 0.001). (C) The interaction between full-length
GST-hHR23A/B and proteasome alpha subunits in Hut78 cell extracts is shown. (D) Relative proteasome activity associated with hHR23A/B was
quantiﬁed and plotted (*, P < 0.001). (E) GST-tagged hHR23A/B, and their UBA1 domains, were incubated with Hut78 extracts and interaction
with multi-Ub protein was determined by immunoblotting. Both hHR23A and UBA1-A formed >twofold increased interaction with multi-Ub
proteins, than hHR23B and UBA1-B.
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similar patterns of interaction with hHR23A and hHR23B
(Fig. 2E). Both hHR23A and UBA1-A (lanes 1 and 3) showed
>2-fold increased binding to high molecular weight multi-Ub
proteins, compared to hHR23B and UBA1-B (lanes 2 and
4). Furthermore, the multi-Ub species bound to hHR23A dis-
played a noticeably higher molecular weight distribution than
the species bound to hHR23B. The signiﬁcance of this diﬀer-
ence is presently unclear.
3.5. UbL forms independent interactions with the proteasome
and ataxin-3
Mutation of lysine-7 in the UbL domain of yeast Rad23
abolished interaction with the proteasome [18]. We generated
a similar mutation in human UbL-A and UbL-B (Fig. 3A),
and examined their interactions with the proteasome. Puriﬁed
GST-UbL mutant proteins (Fig. 3B; UbL-AK8A and UbL-
BK6A) were incubated with Hut78 cell extracts. Consistent with
previous results, mutation of the residue corresponding to
lysine-7 in yeast Rad23 abolished proteasome binding by bothhuman UbL-A and UbL-B (Fig. 3C; lanes 6 and 7), and
resulted in dramatically reduced co-puriﬁcation of proteasome
activity (Fig. 3D, lanes 6 and 7). The diﬀerent proteasome-
binding properties of the un-mutated UbL-A and UbL-B
domains were also conﬁrmed (Fig. 3D; compare lanes 2
and 3). As expected, lower levels of Rpn2, Rpt1 (Fig. 3C; lane
2), and alpha subunits (data not show) were puriﬁed with
UbL-A.
To demonstrate that the reduced proteasome-binding by
UbL-A was not caused by a structural defect, we examined
its interaction with native Ataxin-3 present in the extract, using
the same immunoblots. Ataxin-3 can bind the UbL domains in
both human Rad23 proteins [13], and might encode a protea-
some-associated factor that binds multiubiquitinated proteins
[19]. The immunoblot shown in Fig. 3B was incubated with
antibodies against Ataxin-3 and equivalent binding was ob-
served for both UbL-A and UbL-B, indicating that the UbL
domains were not structurally defective. These results indicate
that distinct residues in UbL contribute to binding Ataxin-3
and the proteasome. The equivalent binding to Ataxin-3
Fig. 3. Conversion of threonine-79 to proline-79 in hHR23A increased proteasome binding. (A) The amino acid sequence of the UbL domains is
shown. Residues that were mutated (K7A, T79P and P77T) are indicated by the arrow. (B,E) GST fusion proteins were puriﬁed from E. coli and
Ponceau S staining revealed purity, and equality of loading. (C) The aﬃnity beads shown in B were incubated with 293 cell lysates, and the bound
proteins were resolved in SDS–PAGE. An immunoblot was incubated with antibodies against proteins shown on the right. (D) Proteasome activity
associated with the puriﬁed GST-fusion proteins shown in C, was determined from ﬁve independent experiments. The value associated with GST-
UbL-A was adjusted to 1, and the relative activity detected with other GST-UbL’s is shown (line 3, 4, 5). No proteasome binding or activity was
detected with UbLK7A (C and D, lanes 6 and 7). Removal of threonine-79 in UbL-A (1–78) increased proteasome binding and activity, to a level
comparable with UbL-B (panels C and D; compare lanes 4 with 2; P < 0.001, and lane 3; P > 0.05). (F). The aﬃnity beads shown in E were incubated
with 293 cell lysates, and the bound proteins characterized by immunoblotting, using antibodies indicated on the right. (G). Proteasome activity for
the reactions shown in F, were generated from eight measurements, and the activity associated with hHR23A was adjusted to 1 (lane 1). The levels
bound to hHR23AT79P increased to hHR23B levels (compare lane 2 with 1; P < 0.01, and lane 3 with 2; P > 0.05), while the activity associated with
hHR23BP77T was unchanged (lane 4, compare to lane 3).
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binding properties of UbL-A and UbL-B are biologically sig-
niﬁcant. Furthermore, the inhibition of proteasome binding
by the lysine mutation (similar to lysine-7 in yeast Rad23), also
indicates that this mutation does not alter structure, since
interaction with Ataxin-3 was unaﬀected.
We also examined Ataxin-3 interaction with full length
hHR23A and hHR23B (Fig. 3E and F; compare lanes 1 and
3), and conﬁrmed that GST-hHR23A and GST-hHR23B dis-
played diﬀerential binding to the proteasome (Fig. 3F; lanes 1
and 3). Consequently, puriﬁed hHR23A was associated with
reduced proteasome activity (Fig. 3G). Similar to the results
with the puriﬁed UbL domains, hHR23A and hHR23B inter-
action with Ataxin-3 was indistinguishable (Fig. 3F; lanes 1
and 3). These results demonstrate that the biochemical proper-
ties of the isolated UbL domains are recapitulated in the intact
proteins, and suggest that the distinct binding properties con-
ferred by the UbL-A and UbL-B domains are physiologically
relevant.3.6. Threonine-79 in UbL-A is associated with the reduced
proteasome interaction
The amino acid sequences of UbL-A and UbL-B are highly
conserved, although they display dissimilar proteasome-bind-
ing properties. An obvious diﬀerence between UbL-A and -B
is the presence of additional residues at the amino-terminus
in hHR23A (Fig. 3A). To determine if these residues inhibited
interaction with the proteasome we generated a UbL-A deriv-
ative that lacked the additional residues (Ala2 and Val3). Con-
version of these residues to alanine did not alter UbL-A/
proteasome binding (data not shown). However, the cloning
design of the GST-UbL proteins generated a sequence that ter-
minated after 72-VVVMVTKT-79 in UbL-A 1–79, and 72-
VVVMVTKPK-78 in UbL-B 1–78. To investigate if the diﬀerent
carboxy-termini aﬀected proteasome-interaction we prepared
constructs that terminated with the same residue (VVVMVTK;
UbL-A1–78 and UbL-B1–76). Removal of threonine-79 from
UbL-A increased UbL-A1–78/proteasome binding (Fig. 3C;
compare lanes 2 and 4). The associated chymotryptic activity
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showed signiﬁcant increase (mean increase 2.5« 0.25;
P < 0.001). In contrast, proteasome-interaction by UbL-B1–76
was unchanged, and remained high (Fig. 3C; compare lanes
3 and 5). The chymotryptic activity puriﬁed with UbL-A1–78
was lower than UbL-B1–76, although the diﬀerence was not sig-
niﬁcant (P > 0.05). As expected, UbL-A1–78 and UbL-B1–76
formed equivalent interaction with Ataxin-3 (Fig. 3C), demon-
strating that Ataxin-3 and proteasome binding are separate
properties.
We converted threonine-79 in full-length hHR23A to pro-
line (T79P), which is the residue present in hHR23B (see ar-
row in Fig. 3A). Higher amounts of proteasome subunits
(Rpn2 and Rpn1) were co-puriﬁed with GST-hHR23APT79P
(Fig. 3F; lane 2), while the interaction with Ataxin-3 was
unaﬀected. We measured chymotryptic activity that was puri-
ﬁed with GST-hHR23AT79P, GST-hHR23A and GST-
hHR23B (Fig. 3G), and detected signiﬁcantly higher levelsFig. 4. Identiﬁcation of novel UbL interactions in human primary breast canc
incubated with four milligrams of tissue extract prepared from human bre
extracts are shown in the left panel. GST-UbL proteins were incubated with t
(NAT) is shown in the middle panel. Similarly, protein species that bound the
Speciﬁc protein bands were identiﬁed by mass spectrometry (see right panel
while proteins named on the right were isolated with UbL-B. (B) Proteins in
were characterized with antibodies against vimentin and eEF1A. (C) Similarl
UbL-B. The bound proteins were released in SDS-containing buﬀer, resolve
ubiquitin-activating enzyme E1, isopeptidase T, Ataxin-3, a-subunits of thewith hHR23APT79P, compared to native hHR23A (Fig. 3G;
compare lane 2 to lane 1; P < 0.01). The activity associated
with hHR23APT79P did not increase to the levels detected
with GST-hHR23B, although the diﬀerence was not signiﬁ-
cant (lanes 2 and 3; P > 0.05). Thus, a single amino acid res-
idue that is present between the downstream sequences of
hHR23A and UbL-A signiﬁcantly aﬀected proteasome bind-
ing. Intriguingly, a reciprocal substitution in hHR23B, in
which Pro-77 was converted to Thr-77 (GST-hHR23BP77T),
did not reduce proteasome binding and chymotryptic activity
to the levels observed with hHR23A (Fig. 3F and G; lane 4),
suggesting that the negative eﬀect of Thr-79 in hHR23A, may
involve other residues in UbL-A. We also note that altering
hHR23-A/proteasome interaction had no eﬀect on its associ-
ation with multi-Ub proteins (data not shown), consistent
with our previous ﬁnding that Rad23 interactions with the
proteasome and multi-Ub proteins are separable functions
[8].er tissues. GST-UbL-A and GST-UbL-B were puriﬁed from E. coli and
ast cancer and normal adjacent tissue (NAT). (A) Untreated protein
issue extracts and the proﬁle of interacting proteins from normal tissue
UbL domains from breast cancer extracts is shown in the right panel.
). Proteins indicated on the left were detected primarily with UbL-A,
breast cancer tissue extracts that bound GST-UbL-A and GST-UbL-B
y, breast cancer extracts were applied to GST, GST-UbL-A and GST-
d by SDS–PAGE, and an immunoblot probed with antibodies against
20S proteasome, and GST.
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and hHR23B
To further characterize the biochemical properties of Rad23
we incubated UbL-A and UbL-B with protein extracts pre-
pared from primary human breast cancer and normal adjacent
tissues (NAT). The bound proteins were released, resolved in
polyacrylamide gels, and stained with Coomassie blue. As ex-
pected, proteasome subunits were puriﬁed with the UbL do-
mains (data not shown). However, we also puriﬁed novel
cellular proteins from primary tissue extracts (Fig. 4A; lanes
6 and 7). Signiﬁcantly, diﬀerences in these interactions were
observed for UbL-A and UbL-B, in both cancer and in non-
aﬀected neighboring tissues that were derived from the same
patient (Fig. 4A; lanes 4–7). Protein bands detected in breast
cancer tissue extracts were excised and their identity revealed
by mass spectrometry. A subset of candidate proteasome (or
UbL) binding proteins is shown (Fig. 4A; lanes 6 and 7).
UbL-A precipitated Ub-activating enzyme (E1), translation
elongation factors (eEF1A and EF2), and fragments of
BRCA2 (lane 6). Signiﬁcant levels of the stress-inducible factor
Hsp71 were also detected in association with UbL-A. In con-
trast, UbL-B was puriﬁed with Isopeptidase T, fragments of
BRCA1, and various forms of the structural protein vimentin.
BRCA1 is targeted for degradation by the Ub/proteasome
pathway [20,21], and BRCA2 has been reported to be ubiqui-
tinated [22]. Although both UbL-A and UbL-B can bind pro-
teasomes, these ﬁndings suggest that the UbL domains might
interact with compositionally distinct forms of the proteasome,
which could reﬂect their diﬀerent interactions with BRCA1
and BRCA2.
We used an immunoblotting approach to verify the proteo-
mic analysis. GST-UbL fusion proteins were incubated with
cell extracts to purify the proteasome and associated proteins.
The bound proteins were resolved by SDS–PAGE, transferred
to nitrocellulose, and the immunoblots reacted with antibod-
ies against vimentin. Consistent with the proteomic analysis, a
predominant interaction was observed with UbL-B (Fig. 4B;
lanes 1 and 2). In contrast, incubation with antibodies against
translation elongation factor 1A (eEF1A), showed strong
interaction with UbL-A, but signiﬁcantly reduced binding to
UbL-B (Fig. 4B; lanes 1 and 2). These results provide compel-
ling support for the proteomic results in Fig. 4A, which shows
diﬀerential interactions with the UbL domains. To further
verify these results (Fig. 4A, lanes 6 and 7), we also investi-
gated if other interactions (Fig. 4A; lanes 6 and 7), could also
be conﬁrmed immunologically. We incubated GST, GST-
UbL-A and GST-UbL-B with breast cancer tissue extracts,
and incubated an immunoblot with antibodies against E1,
Isopeptidase T, Ataxin-3, and proteasome subunits (a1, 2,
3, 5, 6 and 7). Consistent with results described in Fig. 4B,
we found that Isopeptidase T was only puriﬁed with GST-
UbL-B (Panel C). In contrast, low levels of E1 were detected
with both UbL domains, and high levels of Ataxin-3 were
similarly detected with both domains. Despite this similarity,
the interaction between the UbL domains and the proteasome
was markedly diﬀerent, as illustrated by the dissimilar co-
puriﬁcation of a-subunits of the 20S core proteasome particle
(Fig. 4C). Taken together, these results, which examined the
co-puriﬁcation of E1, Isopeptidase T, Vimentin, eEF1A,
Ataxin-3, and proteasome subunits and activity, provide com-
pelling support for the hypothesis that human Rad23 proteins
are functionally distinct. Our ﬁndings are also consistent withrecent reports which showed that hHR23A can form an exclu-
sive interaction with p53, while Rpn12 was preferentially puri-
ﬁed with hHR23B [23]. Similarly, the HIV-1 Vpr protein
might form a preferred interaction with hHR23A [24]. Collec-
tively, these studies are consistent with our proteomic analy-
sis, which indicates that human Rad23 proteins have unique
functions.4. Discussion
We describe distinct proteasome binding properties for hu-
man HR23A and -B proteins. Although hHR23A and
hHR23B perform overlapping roles in NER, this DNA repair
pathway is not required for survival. Therefore, the inviability
of mice lacking both hHR23A and hHR23B [11], indicates that
they have additional roles that contribute to cell survival. We
determined that hHR23A and hHR23B form distinct interac-
tions with the proteasome, and other cellular proteins. This
unexpected result, demonstrates that hHR23 proteins are not
redundant. These distinct interactions might contribute to
the proteolytic functions proteins that are unrelated to their
role in DNA repair.
A previous study showed that lysine-7 in the yeast Rad23
protein is required for eﬃcient interaction with the protea-
some. Based on the strong sequence conservation among
Rad23 proteins sequences, we constructed similar mutations
in the UbL domains from human hHR23A and hHR23B.
The GST-UbL-AK8A and GST-UbL-BK6A mutant derivatives
were puriﬁed from E. coli and incubated with extracts pre-
pared from Hut78 cells. In agreement with previous results,
we found that neither mutant UbL domain could interact
with the proteasome, attesting to the strong evolutionary con-
servation among this class of proteins. Signiﬁcantly, however,
the interaction between the mutant UbL domains and Ataxin-
3 was unaﬀected, supporting the idea that distinct residues
contribute to these interactions, and conﬁrming that the mu-
tant UbL domains are not structurally impaired. Further-
more, the expression of these proteins was similar to their
wildtype counterparts, indicating that they are not more
unstable or prone to aggregation or precipitation. The distinct
proteasome-binding properties of UbL-A and UbL-B were
associated with the presence of a threonine residue at the car-
boxy-terminus of the UbL-A domain (T79). We converted
this residue to proline, which is present in full-length
hHR23B, and found that the proteasome-binding by
hHR23AT79P increased considerably. Although this mutant
did not bind the proteasome as eﬃciently as hHR23B, the im-
proved binding was clear. It is also signiﬁcant that this muta-
tion improved interaction with the proteasome in the context
of the native protein because it is likely that the structural
integrity of the protein domains were maintained. It is inter-
esting, however, that conversion of the proline residue in
hHR23B to threonine (which is present in hHR23A), did
not reduce interaction with the proteasome. This diﬀerence
might be due to additional intermolecular interactions be-
tween the UbL domain and other sequences in the protein.
It could be signiﬁcant in this regard that the presence of pro-
line could aﬀect ﬂexibility and relative positioning of the UbL
domain in the intact Rad23 protein.
A proteomic analysis revealed diﬀerences in the protein
factors that interact with hHR23A and hHR23B. Proteins
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trometry (Fig. 4). We presume that most of these interacting
factors are bound to the proteasome. As expected, proteasome
subunits, stress–response proteins (Hsp70 and Hsp71) and
elongation factors, were co-puriﬁed with both UbL-A and
UbL-B in breast cancer protein extracts. However, UbL-A
and UbL-B also formed unique interactions. BRCA1 frag-
ments, VCP/p97 (data not shown), and various forms of
vimentin were puriﬁed primarily with GST-UbL-B. VCP/p97
is a member of a family of AAA-type ATPases that can bind
multi-Ub chains and the proteasome [25].
eEF1A performs an essential function in translation elonga-
tion, although numerous connections between protein synthe-
sis and protein degradation have been reported [26,27]. In
addition, we showed that yeast eEF1A performs an important
role in the co-translational degradation of nascent, misfolded
proteins [28]. We determined that human eEF1A was puriﬁed
primarily with UbL-A (Fig. 4B).
In summary, we show that hHR23 proteins form distinct
interactions with various cellular factors, including protea-
somes, multiubiquitinated proteins, and stress-related factors
(eEF1A and Hsp’s). Although hHR23A and hHR23B have
similar functions in DNA repair, they evidently also perform
distinct functions in vivo. These ﬁndings suggest that a detailed
understanding of human Rad23 function will require charac-
terization of both proteins in cancer, DNA repair and growth
control.
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